MET and brain neoplasm: Treatment with a combination of afatinib and temozolomide suppresses brain tumor formation by inhibiting crosstalk between EGFRvIII, a constitutively active EGFR mutant, and the RTK cross-activation of tyrosine kinase receptor (cMet) (Vengoji et al., 2019).